Recomendation_2017_30_10_2017_HR

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

42.Kirchhof P, Breithardt G, Aliot E, et al. Personalized management of atrial fibrillation: Proceedings from the fourth Atrial Fibrillation competenceNETwork/EuropeanHeartRhythmAssociationconsensus conference.Europace2013;15:1540–1556.

43.Ackerman MJ, Priori SG, Willems S, et al. Heart Rhythm Society, EuropeanHeartRhythmAssociation.HRS/EHRAexpertconsensus statement on the state of genetic testing for the channelopathies andcardiomyopathies:thisdocumentwasdevelopedasapartnership between the Heart Rhythm Society (HRS) and the European Heart RhythmAssociation(EHRA).Europace2011;13:1077–1109.

44.Schotten U., Verheule S., Kirchhof P., Goette A. Pathophysiological mechanismsofatrialfibrillation — ​atranslationalappraisal.Physiol Rev2010

45.Daoud E. G.,BogunF.,GoyalR.,etal.Effectofatrialfibrillationonatrial refractorinessinhumans.Circulation1996;94:1600–1606

46.HaissaguerreM., JaisP.,Shah D. C.,et al. Spontaneous initiation of atrialfibrillationbyectopicbeatsoriginatinginthepulmonaryveins. NEnglJMed1998;339:659–666.

47.Fetsch T, Bauer P, Engberding R, Koch HP, Lukl J, Meinertz T, Oeff M, Seipel L, Trappe HJ, Treese N, Breithardt G. Prevention of atrial fibrillationaftercardioversion:resultsofthePAFACtrial.EurHeartJ 2004;25:1385–1394.

48.Hindricks G, Piorkowski C, Tanner H, Kobza R, Gerds-Li JH, Carbucicchio C, Kottkamp H. Perception of atrial fibrillation before andafterradiofrequencycatheterablation:relevanceofasymptomatic arrhythmiarecurrence.Circulation2005;112:307–313.

49.Kirchhof P, Bax J, Blomstrom-Lundquist C, Calkins H, Camm AJ, CappatoR, CosioF,CrijnsH,Diener HC,GoetteA,Israel CW,Kuck KH, Lip GY, Nattel S, Page RL, Ravens U, Schotten U, Steinbeck G, VardasP,WaldoA,WegscheiderK,WillemsS,BreithardtG. Earlyand comprehensivemanagementofatrialfibrillation:executivesummary oftheproceedingsfromthe2ndAFNET-EHRAconsensusconference ‘researchperspectivesinAF’.EurHeartJ2009;30:2969–2977c.

50.XiongQ,ProiettiM,SenooK,LipGY.Asymptomaticversussymptomatic atrialfibrillation:Asystematicreviewofage/genderdifferencesand cardiovascularoutcomes.IntJCardiol2015;191:172–177.

51.SannaT,DienerHC,PassmanRS,DiLazzaro V,BernsteinRA,Morillo CA,RymerMM,Thijs V,RogersT,BeckersF,LindborgK,Brachmann

641

ГЛАВА4

J,CRYSTALAFInvestigators.Cryptogenicstrokeandunderlyingatrial fibrillation.NEnglJMed2014;370:2478–2486.

52.RizosT,GuntnerJ,JenetzkyE,MarquardtL,ReichardtC,BeckerR, ReinhardtR,HeppT,KirchhofP,AleynichenkoE,RinglebP,HackeW, VeltkampR. Continuousstrokeunitelectrocardiographicmonitoring versus24-hourHolterelectrocardiographyfordetectionofparoxysmal atrialfibrillationafterstroke.Stroke2012;43:2689–2694.

53.GladstoneDJ,SpringM,DorianP,Panzov V,ThorpeKE,HallJ,Vaid H, O’Donnell M, Laupacis A, Cote R, Sharma M, Blakely JA, Shuaib A,Hachinski V,CouttsSB,SahlasDJ,TealP,YipS,SpenceJD,Buck B, Verreault S, Casaubon LK, Penn A, Selchen D, Jin A, Howse D, Mehdiratta M, Boyle K, Aviv R, Kapral MK, Mamdani M, EMBRACE Investigators and Coordinators. Atrial fibrillation in patients with cryptogenicstroke.NEnglJMed2014;370:2467–2477.

54.FribergL,EngdahlJ,Frykman V,SvennbergE,LevinLA,Rosenqvist M. Populationscreeningof75-and76-year-oldmenandwomenfor silentatrialfibrillation(STROKESTOP).Europace2013;15:135–140.

55.KirchhofP.,Lip G. Y.,VanGelder I. C.,etal.Comprehensiveriskreduction inpatientswithatrialfibrillation:Emergingdiagnosticandtherapeutic options.Executivesummaryofthereportfromthe3rdAFNET/EHRA consensusconference.Europace2012;14:8–27.

56.Healey J. S., Connolly S. J., Gold M. R., et al.; ASSERT Investigators. Subclinicalatrialfibrillationandtheriskofstroke.NEnglJMed2012; 366:120–129.

57.BiniciZ.,IntzilakisT.,Nielsen O. W.,etal.Excessivesupraventricular ectopic activity and increased risk of atrial fibrillation and stroke. Circulation2010;121:1904–1911.

58.Fitzmaurice D. A.,Hobbs F. D.,JowettS.,etal.Screeningversusroutine practiceindetectionofatrialfibrillationinpatientsaged65orover: clusterrandomisedcontrolledtrial.BMJ2007;335:383.

59.HobbsFD,FitzmauriceDA,MantJ,MurrayE,JowettS,BryanS,Raftery J,DaviesM,LipG.Arandomisedcontrolledtrialandcosteffectiveness studyofsystematicscreening(targetedandtotalpopulationscreening) versusroutinepracticeforthedetectionofatrialfibrillationinpeople aged 65 and over. The SAFE study. Health Technol Assess 2005;9: III–IV,IX–X,1–74.

60.JabaudonD.,SztajzelJ.,SievertK., et al. Usefulness of ambulatory 7-dayECGmonitoringforthedetectionofatrialfibrillationandflutter

642

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

after acute stroke and transient ischemic attack. Stroke 2004; 35: 1647–1651.

61.DavisRC,HobbsFD,KenkreJE,RoalfeAK,IlesR,LipGY,DaviesMK. Prevalenceofatrialfibrillationinthegeneralpopulationandinhigh-risk groups:theECHOESstudy.Europace2012;14:1553–1559.

62.Hindricks G., Pokushalov E., Urban L., et al. Performance of a new leadlessimplantablecardiacmonitorindetectingandquantifyingatrial fibrillation—results​oftheXPECTtrial.CircArrhythmElectrophysiol 2010;3:141–147.

63.EngdahlJ,AnderssonL,MirskayaM,RosenqvistM. Stepwisescreening ofatrialfibrillationina75-year-oldpopulation:implicationsforstroke prevention.Circulation2013;127:930–937.

64.KaleschkeG,HoffmannB,Drewitz I,SteinbeckG,NaebauerM,Goette A, Breithardt G, Kirchhof P. Prospective, multicentre validation of a simple, patientoperated electrocardiographic system for the detectionofarrhythmiasandelectrocardiographicchanges.Europace 2009;11:1362–1368.

65.TielemanRG,PlantingaY,RinkesD,Bartels GL,PosmaJL,Cator R, HofmanC,HoubenRP.Validationandclinicaluseofanoveldiagnostic deviceforscreeningofatrialfibrillation.Europace2014;16:1291–1295.

66.Barrett PM, Komatireddy R, Haaser S, Topol S, Sheard J, Encinas J, FoughtAJ,TopolEJ.Comparisonof24-hourHoltermonitoringwith 14-daynoveladhesivepatchelectrocardiographicmonitoring.AmJ Med2014;127:95.e11–97.

67.Lowres N, Neubeck L, Salkeld G, Krass I, McLachlan AJ, Redfern J, BennettAA,BriffaT,BaumanA,MartinezC,WallenhorstC,LauJK, BriegerDB,SyRW,FreedmanSB.Feasibilityandcost-effectivenessof strokepreventionthroughcommunityscreeningforatrialfibrillation using iPhone ECG in pharmacies. The SEARCH-AF study. Thromb Haemost2014;111:1167–1176.

68.QuinnFR,GladstoneD. Screeningforundiagnosedatrialfibrillation inthecommunity.CurrOpinCardiol2014;29:28–35.

69.Daoud EG, Glotzer TV, Wyse DG, Ezekowitz MD, Hilker C, Koehler J, Ziegler PD. Temporal relationship of atrial tachyarrhythmias, cerebrovascularevents,andsystemicembolibasedonstoreddevice data:asubgroupanalysisofTRENDS.HeartRhythm2011;8:1416–1423.

70.Sposato LA, Cipriano LE, Saposnik G, Ruiz Vargas E, Riccio PM, Hachinski V. Diagnosisofatrialfibrillationafterstrokeandtransient

643

ГЛАВА4

ischaemic attack: a systematic review and meta-analysis. Lancet Neurol2015;14:377–387.

71.ThijsVN,BrachmannJ,MorilloCA,PassmanRS,SannaT,BernsteinRA, DienerHC,DiLazzaro V,RymerMM,HoggeL,RogersTB,ZieglerPD, AssarMD.Predictorsforatrialfibrillationdetectionaftercryptogenic stroke:ResultsfromCRYSTALAF.Neurology2016;86:261–269.

72.Adams HP Jr, Bendixen BH, Kappelle LJ, Biller J, Love BB, Gordon DL,MarshEEIII.Classificationofsubtypeofacuteischemicstroke. Definitionsforuseinamulticenterclinicaltrial.TOAST.TrialofOrg 10172inAcuteStrokeTreatment.Stroke1993;24:35–41.

73.Hart RG, Diener HC, Coutts SB, Easton JD, Granger CB, O’Donnell MJ,SaccoRL,ConnollySJ,CryptogenicStroke/ESUSInternational WorkingGroup.Embolicstrokesofundeterminedsource:thecase foranewclinicalconstruct.LancetNeurol2014;13:429–438.

74.BunSS,LatcuDG,MarchlinskiF,SaoudiN. Atrialflutter:morethan justoneofakind.EurHeartJ2015;36:2356–2363.

75.GranadaJ,UribeW,ChyouPH,MaassenK,VierkantR,SmithPN,Hayes J,EakerE,VidailletH. Incidenceandpredictorsofatrialflutterinthe generalpopulation.JAmCollCardiol2000;36:2242–2246.

76.Halligan SC, Gersh BJ, Brown RD Jr, Rosales AG, Munger TM, Shen WK,HammillSC,FriedmanPA.Thenaturalhistoryofloneatrialflutter. AnnInternMed2004;140:265–268.

77.SenooK,LipGY,LaneDA,BullerHR,KotechaD. Residualriskofstroke anddeathinanticoagulatedpatientsaccordingtothetypeofatrial fibrillation:AMADEUSTrial.Stroke2015;46:2523–2528.

78.VanasscheT,LauwMN,EikelboomJW,HealeyJS,HartRG,AlingsM, AvezumA,Diaz R,HohnloserSH, LewisBS,ShestakovskaO, Wang J,ConnollySJ.Riskofischaemicstrokeaccordingtopatternofatrial fibrillation:analysisof6563aspirintreatedpatientsinACTIVE-Aand AVERROES.EurHeartJ2015;36:281–287a.

79.Banerjee A, Taillandier S, Olesen JB, Lane DA, Lallemand B, Lip GY, FauchierL. Patternofatrialfibrillationandriskofoutcomes:theLoire ValleyAtrialFibrillationProject.IntJCardiol2013;167:2682–2687.

80.LeeG,SandersP,KalmanJM.Catheterablationofatrialarrhythmias: stateoftheart.Lancet2012;380:1509–1519.

81.WyseDG,VanGelderIC,EllinorPT,GoAS,KalmanJM,NarayanSM, NattelS,SchottenU,RienstraM. Loneatrialfibrillation:doesitexist? JAmCollCardiol2014;63:1715–1723.

644

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

82.Andrade J, Khairy P, Dobrev D, Nattel S. The clinical profile and pathophysiology of atrial fibrillation: relationships among clinical features,epidemiology,andmechanisms.CircRes2014;114:1453– 1468.

83.DorianP,JungW,NewmanD,PaquetteM,WoodK,AyersGM,Camm J,AkhtarM,LuderitzB. Theimpairmentofhealth-relatedqualityof lifeinpatientswithintermittentatrialfibrillation:implicationsforthe assessmentofinvestigationaltherapy.JAmCollCardiol2000;36:1303– 1309.

84.SearsSF,SerberER,AlvarezLG,SchwartzmanDS,HoytRH,Ujhelyi MR.Understandingatrialsymptomreports:objectiveversussubjective predictors.PacingClinElectrophysiol2005;28:801–807.

85.PeinadoR,ArribasF,OrmaetxeJM,Badia X. Variationinqualityoflife withtypeofatrialfibrillation.RevEspCardiol2010;63:1402–1409.

86.Steg PG, Alam S, Chiang CE, Gamra H, Goethals M, Inoue H, Krapf L, Lewalter T, Merioua I, Murin J, Naditch-Brule L, Ponikowski P, Rosenqvist M, Silva-Cardoso J, Zharinov O, Brette S, Neill JO, RealiseAF investigators. Symptoms, functional status and quality oflifeinpatients withcontrolledand uncontrolledatrialfibrillation: datafromtheRealiseAFcross-sectionalinternationalregistry.Heart 2012;98:195–201.

87.GronefeldGC,LilienthalJ,KuckKH,HohnloserSH,Pharmacological InterventioninAtrialFibrillation(PIAF)Studyinvestigators.Impactof rateversusrhythmcontrolonqualityoflifeinpatientswithpersistent atrial fibrillation.Results froma prospectiverandomizedstudy. Eur HeartJ2003;24:1430–1436.

88.PepineCJ.Effectsofpharmacologictherapyonhealth-relatedquality of life in elderly patients with atrial fibrillation: a systematic review of randomized and nonrandomized trials. Clin Med Insights Cardiol 2013;7:1–20.

89.HagensVE,RanchorAV,VanSonderenE,BoskerHA,KampO,Tijssen JG,KingmaJH,CrijnsHJ,VanGelderIC,RACEStudyGroup.Effectof rateorrhythmcontrolonqualityoflifeinpersistentatrialfibrillation. ResultsfromtheRateControlVersusElectricalCardioversion(RACE) Study.JAmCollCardiol2004;43:241–247.

90.WeerasooriyaR,DavisM,PowellA,Szili-TorokT,ShahC,WhalleyD, Kanagaratnam L, HeddleW, Leitch J, Perks A, Ferguson L, Bulsara M. The Australian intervention randomized control of rate in atrial fibrillationtrial(AIRCRAFT).JAmCollCardiol2003;41:1697–1702.

645

ГЛАВА4

91.Jones DG, Haldar SK, Hussain W, Sharma R, Francis DP, RahmanHaley SL, McDonagh TA, Underwood SR, Markides V, Wong T. A randomized trial to assess catheter ablation versus rate control in themanagementofpersistentatrialfibrillationinheartfailure.JAm CollCardiol2013;61:1894–1903.

92.RienstraM,LubitzSA,MahidaS,MagnaniJW,FontesJD,SinnerMF, VanGelderIC,EllinorPT,BenjaminEJ.Symptomsandfunctionalstatus ofpatientswithatrialfibrillation:stateoftheartandfutureresearch opportunities.Circulation2012;125:2933–2943.

93.KirchhofP,AuricchioA,BaxJ,CrijnsH,CammJ,DienerHC,GoetteA, HindricksG,HohnloserS,KappenbergerL,KuckKH,LipGY,Olsson B,MeinertzT,PrioriS,RavensU,SteinbeckG,SvernhageE,Tijssen J, Vincent A, Breithardt G. Outcome parameters for trials in atrial fibrillation:executivesummary.EurHeartJ2007;28:2803–2817.

94.Kirchhof P, Ammentorp B, Darius H, De Caterina R, Le Heuzey JY, SchillingRJ,SchmittJ,ZamoranoJL.Managementofatrialfibrillation in seven European countries after the publication of the 2010 ESC Guidelines on atrial fibrillation: primary results of the PREvention oFthromboemolicevents— ​EuropeanRegistryinAtrialFibrillation (PREFERinAF).Europace2014;16:6–14.

95.LipGY,LarocheC,PopescuMI,RasmussenLH,Vitali-SerdozL,Dan GA,KalarusZ,CrijnsHJ,OliveiraMM,TavazziL,MaggioniAP,Boriani G. ImprovedoutcomeswithEuropeanSocietyofCardiologyguideline- adherentantithrombotictreatmentinhigh-riskpatientswithatrial fibrillation:areportfromtheEORP-AFGeneralPilotRegistry.Europace 2015;17:1777–1786.

96.HendriksJM,deWitR,CrijnsHJ,VrijhoefHJ,PrinsMH,PistersR,Pison LA,BlaauwY,TielemanRG.Nurse-ledcarevs.usualcareforpatients withatrialfibrillation:resultsofarandomizedtrialofintegratedchronic carevs.routineclinicalcareinambulatorypatientswithatrialfibrillation. EurHeartJ2012;33:2692–2699.

97.Hendriks J, Tomini F, van Asselt T, Crijns H, Vrijhoef H. Costeffectivenessofaspecializedatrialfibrillationclinicvs.usualcarein patientswithatrialfibrillation.Europace2013;15:1128–1135.

98.Tran HN, Tafreshi J, Hernandez EA, Pai SM, Torres VI, Pai RG. A multidisciplinaryatrialfibrillationclinic.CurrCardiolRev2013;9:55–62.

99.ContiA,CanutiE,MarianniniY,VivianiG,PoggioniC,Boni V,PiniR,Vanni S, PadelettiL,GensiniGF. Clinical management ofatrialfibrillation:

646

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

early interventions, observation, and structured follow-up reduce hospitalizations.AmJEmergMed2012;30:1962–1969.

100.CarterL,GardnerM,MageeK,FearonA,Morgulis I,DoucetteS,Sapp JL, Gray C, Abdelwahab A, Parkash R. An Integrated Management ApproachtoAtrialFibrillation.JAmHeartAssoc2016;5:e002950.

101.WagnerEH,AustinBT,VonKorffM. Organizingcareforpatientswith chronicillness.MilbankQ1996;74:511–544.

102.NunoR,ColemanK,BengoaR,SautoR. Integratedcareforchronic conditions: the contribution of the ICCC Framework. Health Policy 2012;105:55–64.

103.Bartel T, Erbel R, Acute Trial Investigators. Transoesophageal echocardiographyforimmediateandsafecardioversioninpatients withatrialfibrillation.EurHeartJ2001;22:2041–2044.

104.HughesM.,Lip G. Y. Strokeandthromboembolisminatrialfibrillation: asystematicreviewofstrokeriskfactors,riskstratificationschema andcosteffectivenessdata.ThrombHaemost2008;99:295–304.

105.Stroke in AF working group. Independent predictors of stroke in patientswithatrialfibrillation:asystematicreview.Neurology2007; 69:546–554.

106.DicksteinK.,Cohen-SolalA.,FilippatosG.,etal.ESCGuidelinesfor thediagnosisandtreatmentofacuteandchronicheartfailure2008: theTaskForcefortheDiagnosisandTreatmentofAcuteandChronic HeartFailure2008oftheEuropeanSocietyofCardiology.Developed incollaborationwiththeHeartFailureAssociationoftheESC(HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM).EurHeartJ2008;29:2388–2442.

107.SchmittJ.,DurayG.,Gersh B. J.,Hohnloser S. H. Atrialfibrillationin acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009; 30: 1038–1045.

108.The SPAF III Writing Committee for the Stroke Prevention in Atrial FibrillationInvestigators.Patientswithnonvalvularatrialfibrillation atlowriskofstrokeduringtreatmentwithaspirin:StrokePrevention inAtrialFibrillation IIIStudy.JAMA1998;279:1273–1277.

109.GageBF,WatermanAD,ShannonW,BoechlerM,RichMW,RadfordMJ. Validationofclinicalclassificationschemesforpredictingstroke:results fromtheNationalRegistryofAtrialFibrillation.JAMA2001;285:2864– 2870.

647

ГЛАВА4

110.vanWalravenC,HartRG,WellsGA,PetersenP,KoudstaalPJ,Gullov AL,HellemonsBS,KoefedBG,LaupacisA.Aclinicalpredictionruleto identifypatientswithatrialfibrillationandalowriskforstrokewhile takingaspirin.ArchInternMed2003;163:936–943.

111.WangTJ,MassaroJM,LevyD,VasanRS,WolfPA,D’AgostinoRB,Larson MG,KannelWB,BenjaminEJ.Ariskscoreforpredictingstrokeordeath inindividualswithnew-onsetatrialfibrillationinthecommunity:the FraminghamHeartStudy.JAMA2003;290:1049–1056.

112.Lip GY, Nieuwlaat R, Pisters R, Lane DA, Crijns HJ. Refining clinical riskstratificationforpredictingstrokeandthromboembolisminatrial fibrillationusinganovelriskfactor-basedapproach:theeuroheart surveyonatrialfibrillation.Chest2010;137:263–272.

113.HartRG,PearceLA,AguilarMI.Meta-analysis:antithrombotictherapy topreventstrokeinpatientswhohavenonvalvularatrialfibrillation. AnnInternMed2007;146:857–867.

114.RuffCT,GiuglianoRP,BraunwaldE,etal.Comparisonoftheefficacy andsafetyofneworalanticoagulantswithwarfarininpatientswith atrialfibrillation:ameta-analysisofrandomisedtrials.Lancet2014;383: 955–962.

115.LipGY,LarocheC,IoachimPM,RasmussenLH,Vitali-SerdozL,Petrescu L,DarabantiuD,CrijnsHJ,KirchhofP,VardasP,TavazziL,Maggioni AP,BorianiG. Prognosisandtreatmentofatrialfibrillationpatientsby Europeancardiologists:oneyearfollow-upoftheEURObservational ResearchProgramme-AtrialFibrillationGeneralRegistryPilotPhase (EORP-AFPilotregistry).EurHeartJ2014;35:3365–3376.

116.KirchhofP,NabauerM,GerthA,LimbourgT,LewalterT,GoetteA, Wegscheider K, Treszl A, Meinertz T, Oeff M, Ravens U, Breithardt G,SteinbeckG. ImpactofthetypeofcentreonmanagementofAF patients:surprisingevidencefordifferencesinantithrombotictherapy decisions.ThrombHaemost2011;105:1010–1023.

117.Lip GY, Al-Khatib SM, Cosio FG, Banerjee A, Savelieva I, Ruskin J, BlendeaD,NattelS,DeBonoJ,ConroyJM,HessPL,GuaschE,Halperin JL, Kirchhof P, MD GC, Camm AJ. Contemporary management of atrial fibrillation: what can clinical registries tell us about stroke preventionandcurrenttherapeuticapproaches?JAmHeartAssoc 2014;3:e001179.

118.Gorst-RasmussenA,SkjothF,LarsenTB,RasmussenLH,LipGY,Lane DA.Dabigatranadherenceinatrialfibrillationpatientsduringthefirst

648

ДИАГНОСТИКАИЛЕЧЕНИЕФИБРИЛЛЯЦИИПРЕДСЕРДИЙ

yearafterdiagnosis:anationwidecohortstudy.JThrombHaemost 2015;13:495–504.

119.OlesenJB,LipGY,HansenML,HansenPR,TolstrupJS,Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C. Validationofriskstratificationschemesforpredictingstrokeand thromboembolisminpatientswithatrialfibrillation:nationwidecohort study.BMJ2011;342:d124.

120.ChaoTF,LiuCJ,WangKL,LinYJ,ChangSL,LoLW,HuYF,TuanTC, Chen TJ, Lip GY, Chen SA. Should atrial fibrillation patients with 1 additionalriskfactoroftheCHA2DS2-VAScscore(beyondsex)receive oralanticoagulation?JAmCollCardiol2015;65:635–642.

121.Lip GY, Skjoth F, Rasmussen LH, Larsen TB. Oral anticoagulation, aspirin,ornotherapyinpatientswithnonvalvularAFwith0or1stroke risk factor based on the CHA2DS2-VASc score. J Am Coll Cardiol 2015;65:1385–1394.

122.FauchierL,LecoqC,ClementyN,BernardA,AngoulvantD,IvanesF, BabutyD,LipGY.OralAnticoagulationandtheRiskofStrokeorDeath inPatientsWithAtrialFibrillationandOneAdditionalStrokeRiskFactor: TheLoireValleyAtrialFibrillationProject.Chest2016;149:960–968.

123.JoundiRA,CiprianoLE,SposatoLA,SaposnikG,StrokeOutcomes ResearchWorkingGroup.IschemicStrokeRiskinPatientsWithAtrial FibrillationandCHA2DS2-VASc Scoreof1: Systematic Reviewand Meta-Analysis.Stroke2016;47:1364–1367.

124.HijaziZ,OldgrenJ,AnderssonU,ConnollySJ,EzekowitzMD,Hohnloser SH,ReillyPA,VinereanuD,SiegbahnA,YusufS,WallentinL. Cardiac biomarkers are associated with an increased risk of stroke and deathinpatientswithatrialfibrillation:aRandomizedEvaluationof Long-term Anticoagulation Therapy (RE-LY) substudy. Circulation 2012;125:1605–1616.

125.Hijazi Z, Wallentin L, Siegbahn A, Andersson U, Christersson C, EzekowitzJ,GershBJ,HannaM,HohnloserS,HorowitzJ,HuberK, Hylek EM, Lopes RD, McMurray JJ, Granger CB. N-terminal pro-B- type natriuretic peptide for risk assessment in patients with atrial fibrillation: insights from the ARISTOTLE Trial (Apixaban for the Prevention of Stroke in Subjects With Atrial Fibrillation). J Am Coll Cardiol2013;61:2274–2284.

126.Hijazi Z, Lindback J, Alexander JH, Hanna M, Held C, Hylek EM, Lopes RD, Oldgren J, Siegbahn A, Stewart RA, White HD, Granger CB,WallentinL,ARISTOTLEandSTABILITYInvestigators.TheABC

649

ГЛАВА4

(age, biomarkers, clinical history) stroke risk score: a biomarkerbasedriskscoreforpredicting strokeinatrialfibrillation. EurHeart

J2016;37:1582–1590.

127.GageBF,YanY,MilliganPE,WatermanAD,CulverhouseR,RichMW, RadfordMJ.Clinicalclassificationschemesforpredictinghemorrhage: results from the National Registry of Atrial Fibrillation (NRAF). Am HeartJ2006;151:713–719.

128.Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A noveluserfriendlyscore(HAS-BLED)toassess1-yearriskofmajor bleedinginpatientswithatrialfibrillation:theEuroHeartSurvey.Chest 2010;138:1093–1100.

129.FangMC,GoAS,ChangY,BorowskyLH,PomernackiNK,Udaltsova N, Singer DE. A new risk scheme to predict warfarin-associated hemorrhage: The ATRIA (Anticoagulation and Risk Factors in Atrial Fibrillation)Study.JAmCollCardiol2011;58:395–401.

130.FribergL,RosenqvistM,LipGY.Evaluationofriskstratificationschemes for ischaemic stroke and bleeding in 182 678 patients with atrial fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J 2012;33:1500–1510.

131.HijaziZ,OldgrenJ,LindbackJ,AlexanderJH,ConnollySJ,Eikelboom JW, Ezekowitz MD, Held C, Hylek EM, Lopes RD, Siegbahn A, Yusuf S,GrangerCB,WallentinL,ARISTOTLEandRE-LYInvestigators.The novelbiomarker-basedABC(age,biomarkers,clinicalhistory)-bleeding riskscoreforpatientswithatrialfibrillation:aderivationandvalidation study.Lancet2016;387:2302–2311.

132.Hart R. G., Pearce L. A., Aguilar M. I. Metaanalysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation.AnnInternMed2007;146:857–867.

133.Granger C. B.,Alexander J. H.,McMurrayJ.J.,etal.,fortheARISTOTLE CommitteesandInvestigators.Apixabanversuswarfarininpatients withatrialfibrillation.NEnglJMed2011;365:981–992.

134.Connolly S. J., Eikelboom J., Joyner C., et al.; AVERROES Steering Committee and Investigators. Apixaban in patients with atrial fibrillation.NEnglJMed2011;364:806–817.

135.Connolly S. J.,Ezekowitz M. D.,YusufS.,etal.Dabigatranversuswarfarin inpatientswithatrialfibrillation.NEnglJMed2009;361:1139–1151.

136.vanWalravenC.,Hart R. G.,ConnollyS.,etal.Effectofageonstroke preventiontherapyinpatientswithatrialfibrillation.Stroke2009;40: 1410–1416.

650